ReviewAddiction (Abingdon, England)2017
Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?
Review in Addiction (Abingdon, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Threats to external validity in the neuroprediction of substance use treatment outcomes.The American journal of drug and alcohol abuse · 2023Pooled it
- Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.Addiction (Abingdon, England) · 2020Pooled it
- Individualized assignment to short-term alcohol abstinence: A proof-of-concept human laboratory study using psychopathology dimensions.Drug and alcohol dependence reports · 2026Article
- Individual variations in motives for nicotine self-administration in male rats: evidence in support for a precision psychopharmacology.Translational psychiatry · 2024Article
- RNA biomarkers for alcohol use disorder.Frontiers in molecular neuroscience · 2022Review
- Lost in Translation: the Gap Between Neurobiological Mechanisms and Psychosocial Treatment Research for Substance Use Disorders.Current addiction reports · 2021Article
- Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.Medicina (Kaunas, Lithuania) · 2021Review
- The future of translational research on alcohol use disorder.Addiction biology · 2021Article
- Topic Evolution Analysis for Omics Data Integration in Cancers.Frontiers in cell and developmental biology · 2021Article
- In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing.Current psychopharmacology · 2020Article
- Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder.Frontiers in psychiatry · 2020Article
- Genomics and Transcriptomics: The Powerful Technologies in Precision Medicine.International journal of general medicine · 2020Review
- Pharmacogenetics of alcohol use disorder treatments: an update.Expert opinion on drug metabolism & toxicology · 2019Review
- Salivary microRNAs identified by small RNA sequencing and machine learning as potential biomarkers of alcohol dependence.Epigenomics · 2019Article
- State-of-the-art behavioral and pharmacological treatments for alcohol use disorder.The American journal of drug and alcohol abuse · 2019Review
- Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.Pharmacogenomics · 2018Article
- New steps for treating alcohol use disorder.Psychopharmacology · 2018Review
- Clinical application of pharmacogenetics in pain management.Personalized medicine · 2018Article
- Biosignature Discovery for Substance Use Disorders Using Statistical Learning.Trends in molecular medicine · 2018Review
- Chronic Alcohol, Intrinsic Excitability, and Potassium Channels: Neuroadaptations and Drinking Behavior.Handbook of experimental pharmacologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsPrecision, personalized or stratified medicine, which promises to deliver the right treatment to the right patient, is a topic of international interest in both the lay press and the scientific literature. A key aspect of precision medicine is the identification of biomarkers that predict the response to medications (i.e. pharmacogenetics). We examined why, despite the great strides that have been made in biomarker identification in many areas of medicine, only in oncology has there been substantial progress in their clinical implementation. We also considered why progress in this effort has lagged in addiction medicine.
methodsWe compared the development of pharmacogenetic biomarkers in oncology, cardiovascular medicine (where developments are also promising) and addictive disorders.
resultsThe first major reason for the success of oncologic pharmacogenetics is ready access to tumor tissue, which allows in-vitro testing and insights into cancer biology. The second major reason is funding, with cancer research receiving, by far, the largest allocation by the National Institutes of Health (NIH) during the past two decades. The second largest allocation of research funding has gone to cardiovascular disease research. Addictions research received a much smaller NIH funding allocation, despite the major impact that tobacco use, alcohol consumption and illicit drug use have on the public health and healthcare costs.
conclusionsGreater support for research on the personalized treatment of addictive disorders can be expected to yield disproportionately large benefits to the public health and substantial reductions in healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.